Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gene Switch Could Repair DNA, Prevent Cancer

By Drug Discovery Trends Editor | February 16, 2016

Damaged DNA strands are shown (Artist representation). Source: Bruce Rolff (123rf)A team of scientists in Japan has found that a DNA modification called 5hmC – thought to be involved in turning genes on and off – localizes at sites of DNA damage and repair. They also found that a family of recently discovered enzymes, called TETs for short, is important in maintaining 5hmC’s reparative role.

To turn genes on or off, a methyl group can be added to or removed from DNA. During the removal of this chemical tag, called demethylation, the methyl group is converted to 5hmC as an intermediate step. The TET enzymes are thought to be critical to the demethylation process. Recent research has shown that 5hmC is associated with an “opening up” of nearby chromatin, the tightly packaged assembly of proteins and DNA in the cell nucleus.

The team reveals in the journal Cell Reports that 5hmC localizes near breaks in DNA that develop naturally or that are caused by DNA-damaging drugs or irradiation. They also found that inhibiting TET enzymes in cells resulted in a lack of 5hmC, followed by errors in chromosome separation. This suggests that TET enzymes are important for the production of 5hmC at DNA damage sites and that both play critical roles in responding to DNA damage.

The research raises the possibility that 5hmC helps to keep chromatin “open” so it can be more accessible to other DNA damage response proteins. 5hmC could be used as a marker for DNA damage, say the researchers.

“Our results imply that loss of TET enzymes and 5hmC depletion could contribute significantly to genome instability and inaccurate chromosome segregation, perhaps explaining the correlation of low 5hmC levels with cancer,” say the researchers.

Source: Kyoto University


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE